In February 2002,
Pharmacia, the then-parent of Sugen, prematurely ended
phase III clinical trials of semaxinib in the treatment of advanced
colorectal cancer due to discouraging results.[2] Other studies, at earlier phases, have since been conducted.[3][4] However, due to the prospect of next-generation tyrosine kinase inhibitors and the inefficacy of semaxanib in clinic trials, further development of the drug has been discontinued.[5] A related compound, SU11248 (
sunitinib), was further developed by Sugen and subsequently by
Pfizer, and received FDA approval for treatment of renal carcinoma in January 2006.[6]
When combined with chronic exposure to
hypoxia, SU5416 induces severe
pulmonary hypertension in
mice and
rats. This property has been exploited to develop a series of useful, though controversial,
rodent models of pulmonary arterial hypertension, the first and best characterized being the Sugen/Hypoxia (SuHx) mouse model.[7][8]
References
^World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85". WHO Drug Information. 15 (2).
"Full text"(PDF). Archived from
the original(PDF) on 2007-03-16. (244
KiB)
^Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML (April 2006). "Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer". American Journal of Clinical Oncology. 29 (2): 109–15.
doi:
10.1097/01.coc.0000199882.53545.ac.
PMID16601426.
S2CID26566099.